Follow-up after stopping entecavir or tenofovir for chronic hepatitis B
Observes adults with chronic hepatitis B after they stop entecavir or tenofovir treatment.
Plain-language title generated from the registry record
Registry title: Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b
Key facts
- Where
- Guangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT02883647, who can take part
Where in China
- The Third Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Third Affiliated Hospital, Sun Yat-Sen University
- Trial code
- NCT02883647
- Record updated
- 29 November 2024
- Original description
The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.Read full original descriptionShow less
Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b
The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.
Inclusion: Patients received anti-HBV therapy with nucleos(t)ide analogs; Last anti-HBV therapy should continue for at least 2 years; For HBeAg positive patients, HBV DNA should keep negative for at least 1 year after HBeAg seroconversion before the therapy ending; for HBeAg negative patients, HBV DNA should keep negative for at least 2 years before the therapy ending.
Exclusion: Patients with other factors causing active liver diseases; Patients with HIV infection or congenital immune deficiency diseases; Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions and other serious complications; Liver cirrhosis, HCC; Pregnancy or lactation.